Chronic Hepatitis D; At a Standstill?

Digestive Diseases

Volumn 34, Issue 4, 2016, Pages 303-307

  Rizzetto, Mario ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Chronic hepatitis D therapy; Hepatitis D; Hepatitis D virus; IFN therapy

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; LONAFARNIB; ANTIVIRUS AGENT; ENZYME INHIBITOR; INTERFERON; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; VIRUS RNA;

ARTICLE; BLOATING; CHRONIC HEPATITIS; CHRONIC HEPATITIS D; DELTA AGENT HEPATITIS; DIARRHEA; ENZYME ACTIVITY; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HUMAN; LIVER CELL; NAUSEA; NONHUMAN; PRENYLATION; PRIORITY JOURNAL; SUMOYLATION; VIRION; ANIMAL; BLOOD; DRUG EFFECTS; HEPATITIS D, CHRONIC; MOUSE; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; ENZYME INHIBITORS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS D, CHRONIC; HEPATITIS DELTA VIRUS; HUMANS; INTERFERONS; MICE; PIPERIDINES; PYRIDINES; RNA, VIRAL;

EID: 84973570810     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000444467     Document Type: Article

References (30)

1. Smedile A, Rizzetto M, Gerin JL: Advances in hepatitis D virus biology and disease. Prog Liver Dis 1994; 12: 157-175.
2. Rizzetto M, Ciancio A: Epidemiology of hepatitis D. Semin Liver Dis 2012; 32: 211-219.
3. Rizzetto M, Alavian SM: Hepatitis delta: the rediscovery. Clin Liver Dis 2013; 17: 475-487.
4. Delgersaikhan Z, Bekhbold D, Bayarmaa O, Dashdorj N, Odgerel O, Naranbaatar D, Dahgwahdorj Y: Highlights from hepatology 2015: from chronic hepatitis to hepatocellular carcinoma. Freiburg, Falk symposium 199, October 14-15, 2015, abstract 62.
5. Taylor JM: Virology of hepatitis D virus. Semin Liver Dis 2012; 32: 195-200.
6. Tseng CH, Lai MM: Hepatitis delta virus RNA replication. Viruses 2009; 1: 818-831.
7. Chang J, Nie X, Chang HE, Han Z, Taylor J: Transcription of hepatitis delta virus RNA by RNA polymerase II. J Virol 2008; 82: 1118-1127.
8. Been MD: HDV ribozymes. Curr Top Microbiol Immunol 2006; 307: 47-65.
9. Casey JL: RNA editing in hepatitis delta virus. Curr Top Microbiol Immunol 2006; 307: 67-89.
10. Huang WH, Chen CW, Wu HL, Chen PJ: Post-translational modification of delta antigen of hepatitis D virus. Curr Top Microbiol Immunol 2006; 307: 91-112.
11. O'Malley B, Lazinski DW: Roles of carboxylterminal and farnesylated residues in the functions of the large hepatitis delta antigen. J Virol 2005; 79: 1142-1153.
12. Niro GA, Rosina F, Rizzetto M: Treatment of hepatitis D. J Viral Hepat 2005; 12: 2-9.
13. Triantos C, Kalafateli M, Nikolopoulou V, Burroughs A: Meta-analysis: antiviral treatment for hepatitis D. Aliment Pharmacol Ther 2012; 35: 663-673.
14. Ilan Y, Klein A, Taylor J, Tur-Kaspa R: Resistance of hepatitis delta virus replication to interferon-alpha treatment in transfected human cells. J Infect Dis 1992; 166: 1164-1166.
15. Han Z, Nogusa S, Nicolas E, Balachandran S, Taylor J: Interferon impedes an early step of hepatitis delta virus infection. PLoS One 2011; 6:e22415.
16. Lamers MH, Kirgiz OO, Heidrich B, Wedemeyer H, Drenth JP: Interferon- for patients with chronic hepatitis delta: a systematic review of randomized clinical trials. Antivir Ther 2012; 17: 1029-1037.
17. Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakalolu Y, Deertekin H, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP; HIDIT Study Group: Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364: 322-331.
18. Wedemeyer H, Yurdaydin C, Ernst S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gurel S, Zeuzem S, Erhardt A, Luth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Ildeman R, Stift J, Heidrich B, Mederacke I, Hardtke S, Koch A, Dienes HP, Manns MP; HIDIT-2 Study Group: Prolonged therapy of hepatitis delta for 96 weeks with PEG-IFNa-2a plus tenofovir or placebo does not prevent HDV RNA relapse: the HIDIT-2 study. J Hepatol 2014; 60:S2-S3.
19. Lunemann S, Malone DF, Grabowski J, Port K, Beziat V, Bremer B, Malmberg KJ, Manns MP, Sandberg JK, Cornberg M, Ljunggren HG, Wedemeyer H, Bjorkstrom NK: Effects of HDV infection and pegylated interferon treatment on the natural killer cell compartment in chronically infected individuals. Gut 2015; 64: 469-482.
20. Visco-Comandini U, Lapa D, Taibi C, Angeletti C, Capobianchi MR, Garbuglia AR: No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance. Dig Liver Dis 2014; 46: 348-352.
21. Guedj J, Rotman Y, Cotler SJ, Koh C, Schmid P, Albrecht J, Haynes-Williams V, Liang TJ, Hoofnagle JH, Heller T, Dahari H: Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Hepatology 2014; 60: 1902-1910.
22. Wobse M, Yurdaydin C, Ernst S, Hardtke S, Heidrich B, Bremer B, Keskin O, Idilman R, Koch A, Manns MP, Wedemeyer H: Early ontreatment HDV-RNA kinetics are not predictive for long-term response to a PEG-IFNa therapy of hepatitis delta. Hepatology 2015; 60: 974A.
23. Heidrich B, Yurdaydn C, Kabacam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalcin K, Gurel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, Wedemeyer H; HIDIT-1 Study Group: Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 2014; 60: 87-97.
24. Ponzetto A, Hoyer BH, Popper H, Engel R, Purcell RH, Gerin JL: Titration of the infectivity of hepatitis D virus in chimpanzees. J Infect Dis 1987; 155: 72-78.
25. Rizzetto M, Smedile A: Pegylated interferon therapy of chronic hepatitis D: in need of revision. Hepatology 2015; 61: 1109-1111.
26. Ciancio A, Rizzetto M: Chronic hepatitis D at a standstill: where do we go from here? Nat Rev Gastroenterol Hepatol 2014; 11: 68-71.
27. Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, Winters MA, Subramanya G, Cooper SL, Pinto P, Wolff EF, Bishop R, Ai Thanda Han M, Cotler SJ, Kleiner DE, Keskin O, Idilman R, Yurdaydin C, Glenn JS, Heller T: Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis 2015; 15: 1167-1174.
28. Yurdaydin C, Idilman R, Choong I, Kalkan C, Keskin O, Karakaya MF, Tuzun AE, Karatayli E, Bozdayi M, Cory D, Glenn JS: Optimizing the prenylation inhibitor lonafarnib using ritonavir boosting in patients with chronic delta hepatitis. J Hepatol 2015; 62:S235-S261.
29. Volz T, Giersch K, Allweiss L, Bhadra OD, Petersen J, Lohse AW, Lutgehetmann M, Urban S, Dandri M: Myrcludex-B inhibits establishment of HDV super-infection in HBV infected mice and reduces HDV viremia in stably HBV/HDV co-infected mice. J Hepatol 2015; 62:S514.
30. Bazinet M, Pantea V, Cebotarescu V, Cojuhari L, Jimbei P, Vaillant A: Significant reduction of HBsAg and HDV RNA by the nucleic acid polymer REP 2139 in caucasian patients with chronic HBV/HDV co-infection. J Hepatol 2015; 62:S257-S258.